Newron subscription for EUR 5.5M shares under up to EUR 38M financing
Newron said an investor group subscribed for shares worth EUR 5.5 million as part of total financing of up to EUR 38 million. Proceeds are expected to fund ENIGMA-TRS studies and extend cash runway beyond 12-week results.
Total proceeds are expected to fund global ENIGMA-TRS studies and extend the cash runway beyond pivotal 12-week results, supporting development of evenamide as a potential first add-on therapy for treatment-resistant schizophrenia. , Sept. 08, 2026 (GLOBE NEWSWIRE) -- Newron Pharm…